Cargando…

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19) pandemic, serves as the basis for our study, which relies on the Food and Drug Administration Adverse Event Reporting System (FAERS). The objective is to extract adverse event (AE) signals associated with molnupir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Yankun, Ma, Lin, Wang, Yuting, Zheng, Jingping, Su, Ling, Lyu, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644225/ https://www.ncbi.nlm.nih.gov/pubmed/38026949 http://dx.doi.org/10.3389/fphar.2023.1253799

Ejemplares similares

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
por: Fang, Zhihong, et al.
Publicado: (2023)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
por: Guo, Haoning, et al.
Publicado: (2022)

Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)
por: Pera, Victor, et al.
Publicado: (2023)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2023)

Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database
por: Peng, Jing, et al.
Publicado: (2022)

Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System
por: Sakai, Takamasa, et al.
Publicado: (2022)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

Safety Profile of Levonorgestrel: A Disproportionality Analysis of Food and Drug Administration Adverse Event Reporting System (Faers) Database
por: Kurian, Anitha, et al.
Publicado: (2018)

Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system
por: Wu, Ziyang, et al.
Publicado: (2022)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
por: Matsumoto, Kiyoka, et al.
Publicado: (2020)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
por: Wang, Jun, et al.
Publicado: (2023)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2022)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
por: Zhang, Ying, et al.
Publicado: (2023)

Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bian, Sainan, et al.
Publicado: (2021)

Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug−gene Interaction Network
por: Umetsu, Ryogo, et al.
Publicado: (2021)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2019)

Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database
por: Zhou, Zhi-Xuan, et al.
Publicado: (2022)

Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System
por: Li, Xiaotong, et al.
Publicado: (2023)

Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System
por: Yang, Renjun, et al.
Publicado: (2022)

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan
por: Katsuno, Hayato, et al.
Publicado: (2021)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System
por: Wei, Chunyan, et al.
Publicado: (2023)

Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system
por: Wei, Wei, et al.
Publicado: (2023)

Suspected Adverse Drug Reactions Related to Breast Cancer Chemotherapy: Disproportionality Analysis of the Brazilian Spontaneous Reporting System
por: Barcelos, Flávia Campos, et al.
Publicado: (2019)

PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
por: Huang, Guili, et al.
Publicado: (2022)

Variation in adverse drug events of opioids in the United States
por: Liu, Edward Y., et al.
Publicado: (2023)

Antibiotics and antibiotic-associated diarrhea: a real-world disproportionality study of the FDA adverse event reporting system from 2004 to 2022
por: Huang, Haining, et al.
Publicado: (2023)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
por: Guo, Qiang, et al.
Publicado: (2022)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Epirubicin and gait apraxia: a real-world data analysis of the FDA Adverse Event Reporting System database
por: Wang, Wei, et al.
Publicado: (2023)

Prevention of adverse events in the administration of drugs
por: Diano, G, et al.
Publicado: (2010)

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database
por: Liu, Lulu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vfhqp700b5cr2rgrmvj8cn2o48